Corticosteroids in neuro-oncology

Cancer Neurology In Clinical Practice: Neurologic Complications of Cancer and Its Treatment: Second Edition

Volumn , Issue , 2008, Pages 47-56

  Kesari, Santosh ^a   Paleologos, Nina A ^b   Vick, Nicholas A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Evanston Northwestern Healthcare ^*  (United States)

Author keywords

brain tumor; corticosteroids; corticotropin releasing factor; myopathy; neurotoxicity; VEGF inhibitors

Indexed keywords

EID: 77949265856     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-412-4_4     Document Type: Chapter

References (57)

1. Ingraham FD, Matson DD, McLaurin RL. Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. N Engl J Med 1952;246(15):568-571.
2. Kofman S, Garvin JS, Nagamani D et al. Treatment of cerebral metastases from breast carcinoma with prednisolone. J Am Med Assoc 1957;163(16):1473-1476.
3. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet 1961;81:46-53.
4. Vecht CJ, Hovestadt A, Verbiest HB et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994;44(4):675-680.
5. Miller JD, Leech P. Effects of mannitol and steroid therapy on intracranial volume-pressure relationships in patients. J Neurosurg 1975;42(3):274-281.
6. Miller JD, Sakalas R, Ward JD et al. Methylprednisolone treatment in patients with brain tumors. Neurosurgery 1977;1(2):114-117.
7. Yeung WT, Lee TY, Del Maestro RF et al. Effect of steroids on iopamidol blood-brain transfer constant and plasma volume in brain tumors measured with X-ray computed tomography. J Neurooncol 1994;18(1):53-60.
8. Bell BA, Smith MA, Kean DM et al. Brain water measured by magnetic resonance imaging: correlation with direct estimation and changes after mannitol and dexamethasone. Lancet 1987;1(8524):66-69.
9. Gutin PH. Corticosteroid therapy in patients with cerebral tumors: benefits, mechanisms, problems, practicalities. Semin Oncol 1975;2(1):49-56.
10. Vecht CJ, Verbiest HBC. Use of glucocorticoids in neuro-oncology. In: RG Wiley, ed. Neurologic Complications of Cancer. New York: Marcel Dekker; 1995:199-218.
11. Carson JL, Strom BL, Schinnar R et al. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med 1991;91(3):223-228.
12. Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976;294(9):473-179.
13. Conn HO, Poynard T. Adrenocorticosteroid administration and peptic ulcer: a critical analysis. J Chronic Dis 1985;38(6):457-468.
14. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41(8):1235-1239.
15. Vick NA. Steroid toxicity. J Neurooncol 1988;6(2):199.
16. Askari A, Vignos PJ, Jr., Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976;61(4):485-492.
17. Kelly FJ, McGrath JA, Goldspink DF et al. A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle Nerve 1986;9(1):1-10.
18. Koski CL, Rifenberick DH, Max SR. Oxidative metabolism of skeletal muscle in steroid atrophy. Arch Neurol 1974;31(6):407-410.
19. Ruff RL. Endocrine myopathies. In: AG. Engle, BQ Banker, eds. Myology: Basic and Clinical. New York: McGraw-Hill; 1986: 1871-1879.
20. Kimura K, Kanda F, Okuda S et al. Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine synthetase activity in cultured L6 rat skeletal muscle cells. Neurosci Lett 2001;302(2-3): 154-156.
21. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies: an overview of the possible mechanisms. Pharmacol Rep 2005;57(1):23-34.
22. Layzer RB. Neuromuscular Manifestations of Systemic Disease. Philadelphia: FA. Davis 1985.
23. Edman JC, Kovacs JA, Masur H et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988;334(6182):519-522.
24. Thomas CF, Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350(24):2487-2498.
25. Henson JW, Jalaj JK, Walker RW et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991;48(4):406-409.
26. Mathew BS, Grossman SA. Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. Cancer Treat Rev 2003;29(2): 105-119.
27. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996;27(3):235-240.
28. Sepkowitz KA, Brown AE, Telzak EE et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267(6):832-837.
29. Osteoporosis, ACoRAHCoG-I. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum 2001;44(7):1496-1503.
30. Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther 2005;5(6):817-832.
31. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989;62(5):375-391.
32. Irvin W, MacDonald G, Smith JK et al. Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 2007;25(17):2484-2486.
33. Kim JB, Ju JY, Kim JH et al. Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro. Brain Res 2004;1027(1-2):1-10.
34. Sabolek M, Herborg A, Schwarz J et al. Dexamethasone blocks astroglial differentiation from neural precursor cells. Neuroreport 2006;17(16):1719-1723.
35. Chalk JB, Ridgeway K, Brophy T et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984;47(10):1087-1090.
36. Choi Y, Thrasher K, Werk EE et al. Effect of diphenylhydantoin on Cortisol kinetics in humans. J Pharmacol Exp Ther 1971;176(1): 27-34.
37. Haque N, Thrasher K, Werk EE et al. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. J Clin Endocrinol Metab 1972;34(1):44-50.
38. Penry JK, Newmark ME. The use of antiepileptic drugs. Ann Intern Med 1979;90(2):207-218.
39. Klatzo I. Presidental address: neuropathological aspects of brain edema. J Neuropathol Exp Neurol 1967;26(1):1-14.
40. Fishman RA. Steroids in the treatment of brain edema. N Engl J Med 1982;306(6):359-360.
41. Brightman MW, Reese TS, Vick NA et al. A mechanism underlying the lack of a blood-brain barrier to peroxidase in virally induced brain tumors. J Neuropathol Exp Neurol 1971;30(1): 139-140.
42. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967;34(1):207-217.
43. Vick NA. Brain tumor microvasculature. In: L Weiss, HA Gilbert, JG Posner, eds. Brain Metastasis. Boston: G.K. Hall & Company; 1980:115-133.
44. Vick NA, Bigner DD. Microvascular abnormalities in virally induced canine brain tumors: structural bases for altered blood-brain barrier function. J Neurol Sci 1972;17(1):29-39.
45. Wen PY, Schiff D, Kesari S et al. Medical management of patients with brain tumors. J Neuro-oncol 2006;80(3):313-332.
46. Papadopoulos MC, Saadoun S, Binder DK et al. S. Molecular mechanisms of brain tumor edema. Neuroscience 2004;129(4):1011-1020.
47. Machein MR, Plate KH. VEGF in brain tumors. J Neuro-oncol 2000;50(1-2):109-120.
48. Lamszus K, Laterra J, Westphal M et al. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 1999;17(5-6):517-530.
49. Cloughesy TF, Black KL. Peritumoral edema. In: MS. Berger, CB Wilson, eds. The Gliomas. Philadelphia W.B. Saunders; 1999: 107-114.
50. Hedley-Whyte ET, Hsu DW. Effect of dexamethasone on blood-brain barrier in the normal mouse. Ann Neurol 1986;19(4):373-7.
51. Heiss JD, Papavassiliou E, Merrill MJ et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats: involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996;98(6):1400-1408.
52. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25(3):451-468.
53. Hariharan S, Shapiro W, Chang S et al. Phase II randomized dose-ranging trial of human corticotrophin releasing factor in symptomatic brain tumor patients. In: American Academy of Neurology; 2000; p. A12; S06.001.
54. Tjuvajev J, Uehara H, Desai R et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res 1996;56(6): 1352-1360.
55. Villalona-Calero MA, Eckardt J, Burris H et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 1998;9(1):71-77.
56. Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol 2004;57(1):6-13.
57. Portnow J, Suleman S, Grossman SA et al. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro Oncol 2002;4(1):22-25.